Tony L Yaksh

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9239118/publications.pdf

Version: 2024-02-01

240 papers	17,790 citations	12328 69 h-index	15265 126 g-index
258 all docs	258 docs citations	258 times ranked	9801 citing authors

#	Article	IF	Citations
1	Chronic catheterization of the spinal subarachnoid space. Physiology and Behavior, 1976, 17, 1031-1036.	2.1	2,161
2	Behavioral and autonomic correlates of the tactile evoked allodynia produced by spinal glycine inhibition: effects of modulatory receptor systems and excitatory amino acid antagonists. Pain, 1989, 37, 111-123.	4.2	625
3	Upregulation of Dorsal Root Ganglion Î±₂Î´ Calcium Channel Subunit and Its Correlation with Allodynia in Spinal Nerve-Injured Rats. Journal of Neuroscience, 2001, 21, 1868-1875.	3.6	581
4	Pharmacology of spinal adrenergic systems which modulate spinal nociceptive processing. Pharmacology Biochemistry and Behavior, 1985, 22, 845-858.	2.9	569
5	Spinal opiate analgesia: Characteristics and principles of action. Pain, 1981, 11, 293-333.	4.2	518
6	Spinal nitric oxide synthesis inhibition blocks NMDA-induced thermal hyperalgesia and produces antinociception in the formalin test in rats. Pain, 1993, 54, 291-300.	4.2	359
7	Activation of p38 mitogenâ€activated protein kinase in spinal microglia is a critical link in inflammationâ€induced spinal pain processing. Journal of Neurochemistry, 2003, 86, 1534-1544.	3.9	354
8	THESPINALPHOSPHOLIPASE-CYCLOOXYGENASE-PROSTANOIDCASCADE INNOCICEPTIVEPROCESSING. Annual Review of Pharmacology and Toxicology, 2002, 42, 553-583.	9.4	287
9	Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve. Excitatory amino acid antagonists. Pain, 1992, 49, 121-128.	4.2	280
10	Increased Sensitivity of Injured and Adjacent Uninjured Rat Primary Sensory Neurons to Exogenous Tumor Necrosis Factor-Î± after Spinal Nerve Ligation. Journal of Neuroscience, 2003, 23, 3028-3038.	3.6	278
11	The Acute Antihyperalgesic Action of Nonsteroidal, Anti-Inflammatory Drugs and Release of Spinal Prostaglandin E₂Is Mediated by the Inhibition of Constitutive Spinal Cyclooxygenase-2 (COX-2) but not COX-1. Journal of Neuroscience, 2001, 21, 5847-5853.	3.6	274
12	Polyanalgesic Consensus Conference 2012: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel. Neuromodulation, 2012, 15, 436-466.	0.8	241
13	The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines. Neuromodulation, 2017, 20, 96-132.	0.8	241
14	Characterization of variables defining hindpaw withdrawal latency evoked by radiant thermal stimuli. Journal of Neuroscience Methods, 1997, 76, 183-191.	2.5	233
15	Intrathecal minocycline attenuates peripheral inflammationâ€induced hyperalgesia by inhibiting p38 MAPK in spinal microglia. European Journal of Neuroscience, 2005, 22, 2431-2440.	2.6	233
16	Spinal systems and pain processing: development of novel analgesic drugs with mechanistically defined models. Trends in Pharmacological Sciences, 1999, 20, 329-337.	8.7	216
17	Effect of continuous intrathecal infusion of Ï‰-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain, 1995, 60, 83-90.	4.2	203
18	Prolonged Alleviation of Tactile Allodynia by Intravenous Lidocaine in Neuropathic Rats. Anesthesiology, 1995, 83, 775-785..	2.5	190

#	Article	IF	Citations
19	Rapid continuous 3D printing of customizable peripheral nerve guidance conduits. Materials Today, 2018, 21, 951-959.	14.2	173
20	Stereospecific effects of a nonpeptidic NK1 selective antagonist, CP-96,345: Antinociception in the absence of motor dysfunction. Life Sciences, 1991, 49, 1955-1963.	4.3	167
21	Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model. Neuroscience Letters, 1995, 199, 111-114.	2.1	166
22	Inflammatory Masses Associated with Intrathecal Drug Infusion: A Review of Preclinical Evidence and Human Data. Pain Medicine, 2002, 3, 300-312.	1.9	163
23	Chronically Infused Intrathecal Morphine in Dogs. Anesthesiology, 2003, 99, 174-187.	2.5	163
24	A brief comparison of the pathophysiology of inflammatory versus neuropathic pain. Current Opinion in Anaesthesiology, 2011, 24, 400-407.	2.0	160
25	The spinal loop dialysis catheter: characterization of use in the unanesthetized rat. Journal of Neuroscience Methods, 1995, 62, 43-53.	2.5	148
26	In vivo evidence for multiple opiate receptors mediating analgesia in the rat spinal cord. Brain Research, 1982, 247, 75-83.	2.2	146
27	Spinal p38 MAP kinase is necessary for NMDA-induced spinal PGE2 release and thermal hyperalgesia. NeuroReport, 2003, 14, 1153-1157.	1.2	138
28	Spinal p38Î² isoform mediates tissue injuryâ€induced hyperalgesia and spinal sensitization. Journal of Neurochemistry, 2005, 92, 1508-1520.	3.9	133
29	The effect of morphine on formalinâ€evoked behaviour and spinal release of excitatory amino acids and prostaglandin E₂ using microdialysis in conscious rats. British Journal of Pharmacology, 1995, 114, 1069-1075.	5.4	132
30	Characterization of time course of spinal amino acids, citrulline and PGE2 release after carrageenan/kaolin-induced knee joint inflammation: a chronic microdialysis study. Pain, 1996, 67, 345-354.	4.2	131
31	Localization of N-type Ca 2+ channels in the rat spinal cord following chronic constrictive nerve injury. Experimental Brain Research, 2002, 147, 456-463.	1.5	131
32	Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10470-10475.	7.1	131
33	Calcium Channels As Therapeutic Targets in Neuropathic Pain. Journal of Pain, 2006, 7, S13-S30.	1.4	128
34	An automated flinch detecting system for use in the formalin nociceptive bioassay. Journal of Applied Physiology, 2001, 90, 2386-2402.	2.5	127
35	Spinal TLR4 mediates the transition to a persistent mechanical hypersensitivity after the resolution of inflammation in serum-transferred arthritis. Pain, 2011, 152, 2881-2891.	4.2	123
36	The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks. Neuromodulation, 2017, 20, 155-176.	0.8	121

#	Article	IF	Citations
37	Characterization of the acute and persistent pain state present in K/BxN serum transfer arthritis. Pain, 2010, 151, 394-403.	4.2	117
38	Spinal Phosphinositide 3-Kinaseâ€“Aktâ€“Mammalian Target of Rapamycin Signaling Cascades in Inflammation-Induced Hyperalgesia. Journal of Neuroscience, 2011, 31, 2113-2124.	3.6	117
39	Vincristine-induced allodynia in the rat. Pain, 2001, 93, 69-76.	4.2	112
40	Inhibition by Spinal Â- and Â-Opioid Agonists of Afferent-Evoked Substance P Release. Journal of Neuroscience, 2005, 25, 3651-3660.	3.6	112
41	Opioid modulation of capsaicin-evoked release of substance P from rat spinal cord in vivo. Peptides, 1989, 10, 1127-1131.	2.4	108
42	Spinal 12-lipoxygenase-derived hepoxilin A ₃ contributes to inflammatory hyperalgesia via activation of TRPV1 and TRPA1 receptors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6721-6726.	7.1	105
43	Polyanalgesic Consensus Conferenceâ€”2012: Recommendations to Reduce Morbidity and Mortality in Intrathecal Drug Delivery in the Treatment of Chronic Pain. Neuromodulation, 2012, 15, 467-482.	0.8	103
44	Transient Spinal Ischemia in Rat: Characterization of Spinal Cord Blood Flow, Extracellular Amino Acid Release, and Concurrent Histopathological Damage. Journal of Cerebral Blood Flow and Metabolism, 1994, 14, 604-614.	4.3	93
45	Constitutive Spinal Cyclooxygenase-2 Participates in the Initiation of Tissue Injury-Induced Hyperalgesia. Journal of Neuroscience, 2004, 24, 2727-2732.	3.6	93
46	Retrospective consideration of the doses of morphine given intrathecally by chronic infusion in 163 patients by 19 physicians. Pain, 1987, 31, 211-223.	4.2	92
47	Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat. Experimental Neurology, 2004, 185, 160-168.	4.1	91
48	Neuraxial Analgesia in Neonates and Infants. Anesthesia and Analgesia, 2012, 115, 638-662.	2.2	89
49	Concurrent Spinal Infusion of MK801 Blocks Spinal Tolerance and Dependence Induced by Chronic Intrathecal Morphine in the Rat. Anesthesiology, 1996, 84, 1177-1188.	2.5	88
50	Toll-like receptor signaling adapter proteins govern spread of neuropathic pain and recovery following nerve injury in male mice. Journal of Neuroinflammation, 2013, 10, 148.	7.2	88
51	Targeting toll-like receptor-4 (TLR4)â€”an emerging therapeutic target for persistent pain states. Pain, 2018, 159, 1908-1915.	4.2	88
52	Neuraxial Cytokines in Pain States. Frontiers in Immunology, 2019, 10, 3061.	4.8	88
53	Polyanalgesic Consensus Conferenceâ€”2012: Consensus on Diagnosis, Detection, and Treatment of Catheter-Tip Granulomas (Inflammatory Masses). Neuromodulation, 2012, 15, 483-496.	0.8	85
54	The Effect of Intrathecal Gabapentin on Pain Behavior and Hemodynamics on the Formalin Test in the Rat. Anesthesia and Analgesia, 1999, 89, 434-439.	2.2	84

#	Article	IF	Citations
55	The Use of Intrathecal Midazolam in Humans: A Case Study of Process. Anesthesia and Analgesia, 2004, 98, 1536-1545.	2.2	84
56	Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid. Cannabis and Cannabinoid Research, 2016, 1, 102-112.	2.9	84
57	Time Course and Role of Morphine Dose and Concentration in Intrathecal Granuloma Formation in Dogs. Anesthesiology, 2006, 105, 581-589.	2.5	83
58	The search for novel analgesics: targets and mechanisms. F1000prime Reports, 2015, 7, 56.	5.9	83
59	Effects of Intrathecal Ketamine in the Neonatal Rat. Anesthesiology, 2010, 113, 147-159.	2.5	83
60	Opiate Pharmacology of Intrathecal Granulomas. Anesthesiology, 2006, 105, 590-598.	2.5	82
61	Descending serotonergic facilitation of spinal ERK activation and pain behavior. FEBS Letters, 2006, 580, 6629-6634.	2.8	81
62	Anti-allodynic efficacy of the Ï‡-conopeptide, Xen2174, in rats with neuropathic pain. Pain, 2005, 118, 112-124.	4.2	78
63	Therapeutic use of botulinum toxin in migraine: mechanisms of action. British Journal of Pharmacology, 2014, 171, 4177-4192.	5.4	78
64	Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. Pain, 2019, 160, 2210-2220.	4.2	78
65	Spinal phospholipase A2 in inflammatory hyperalgesia: role of Group IVA cPLA2. British Journal of Pharmacology, 2005, 144, 940-952.	5.4	76
66	Effects of Intrathecal NMDA and Non-NMDA Antagonists on Acute Thermal Nociception and Their Interaction with Morphine. Anesthesiology, 1998, 89, 715-722..	2.5	74
67	Transient Spinal Ischemia in the Rat: Characterization of Behavioral and Histopathological Consequences as a Function of the Duration of Aortic Occlusion. Journal of Cerebral Blood Flow and Metabolism, 1994, 14, 526-535.	4.3	73
68	Mechanism of Action of Nonsteroidal Anti-inflammatory Drugs. Cancer Investigation, 1998, 16, 509-527.	1.3	73
69	Antinociceptive effects of intrathecally administered human Î²-endorphin in the rat and cat. Canadian Journal of Physiology and Pharmacology, 1978, 56, 754-759.	1.4	69
70	Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Prostaglandin E2 Release. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 466-475.	2.5	68
71	Persistent Hyperalgesia in the Cisplatin-Treated Mouse as Defined by Threshold Measures, the Conditioned Place Preference Paradigm, and Changes in Dorsal Root Ganglia Activated Transcription Factor 3. Anesthesia and Analgesia, 2013, 116, 224-231.	2.2	68
72	Nonopioid Actions of Intrathecal Dynorphin Evoke Spinal Excitatory Amino Acid and Prostaglandin E2 Release Mediated by Cyclooxygenase-1 and -2. Journal of Neuroscience, 2004, 24, 1451-1458.	3.6	67

#	Article	IF	Citations
73	Inhibition of spinal protein kinase C reduces nerve injury-induced tactile allodynia in neuropathic rats. Neuroscience Letters, 1999, 276, 99-102.	2.1	65
74	The utility of 2-hydroxypropyl-Î²-cyclodextrin as a vehicle for the intracerebral and intrathecal administration of drugs. Life Sciences, 1991, 48, 623-633.	4.3	64
75	Neuraxial Morphine May Trigger Transient Motor Dysfunction after a Noninjurious Interval of Spinal Cord Ischemia. Anesthesiology, 2003, 98, 862-870.	2.5	63
76	Galanin Acts at GalR1 Receptors in Spinal Antinociception: Synergy with Morphine and AP-5. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 574-582.	2.5	63
77	Mechanical allodynia in rats is blocked by a Ca2+ permeable AMPA receptor antagonist. NeuroReport, 1999, 10, 3523-3526.	1.2	62
78	Botulinum toxin B in the sensory afferent: Transmitter release, spinal activation, and pain behavior. Pain, 2014, 155, 674-684.	4.2	62
79	A novel model of primary and secondary hyperalgesia after mild thermal injury in the rat. Neuroscience Letters, 1998, 254, 25-28.	2.1	61
80	Current Status and Future Directions of Botulinum Neurotoxins for Targeting Pain Processing. Toxins, 2015, 7, 4519-4563.	3.4	61
81	Antinociception produced by spinal delivery of the S and R enantiomers of flurbiprofen in the formalin test. European Journal of Pharmacology, 1994, 256, 205-209.	3.5	58
82	In vitroprostanoid release from spinal cord following peripheral inflammation: effects of substance P, NMDA and capsaicin. British Journal of Pharmacology, 1999, 126, 1333-1340.	5.4	58
83	Systemic TAK-242 prevents intrathecal LPS evoked hyperalgesia in male, but not female mice and prevents delayed allodynia following intraplantar formalin in both male and female mice: The role of TLR4 in the evolution of a persistent pain state. Brain, Behavior, and Immunity, 2016, 56, 271-280.	4.1	58
84	Sex differences in neuroimmune and glial mechanisms of pain. Pain, 2021, 162, 2186-2200.	4.2	58
85	Antinociceptive effect of spinally delivered prostaglandin E receptor antagonists in the formalin test on the rat. Neuroscience Letters, 1994, 173, 193-196.	2.1	57
86	Current and Future Issues in the Development of Spinal Agents for the Management of Pain. Current Neuropharmacology, 2017, 15, 232-259.	2.9	57
87	Pharmacology and Toxicology of Chronically Infused Epidural Clonidine Â· HCl in Dogs. Fundamental and Applied Toxicology, 1994, 23, 319-335.	1.8	56
88	Long-lasting analgesia via targeted in situ repression of Na _V 1.7 in mice. Science Translational Medicine, 2021, 13, .	12.4	56
89	Capsaicin-evoked prostaglandin E2 release in spinal cord slices: relative effect of cyclooxygenase inhibitors. European Journal of Pharmacology, 1994, 271, 293-299.	3.5	55
90	Lipid rafts in glial cells: role in neuroinflammation and pain processing. Journal of Lipid Research, 2020, 61, 655-666.	4.2	55

#	Article	IF	Citations
91	Toxicology Evaluation of Drugs Administered via Uncommon Routes: Intranasal, Intraocular, Intrathecal/Intraspinal, and Intra-Articular. International Journal of Toxicology, 2018, 37, 4-27.	1.2	54
92	Toll-like receptor signaling regulates cisplatin-induced mechanical allodynia in mice. Cancer Chemotherapy and Pharmacology, 2014, 73, 25-34.	2.3	52
93	Botulinum toxin blocks mast cells and prevents rosacea like inflammation. Journal of Dermatological Science, 2019, 93, 58-64.	1.9	52
94	Inhibition of Neuroinflammation by AIBP: Spinal Effects upon Facilitated Pain States. Cell Reports, 2018, 23, 2667-2677.	6.4	51
95	Normalization of cholesterol metabolism in spinal microglia alleviates neuropathic pain. Journal of Experimental Medicine, 2021, 218, .	8.5	51
96	Regulation of Spinal Substance P Release by Intrathecal Calcium Channel Blockade. Anesthesiology, 2011, 115, 153-164.	2.5	51
97	Inflammatory hyperalgesia induces essential bioactive lipid production in the spinal cord. Journal of Neurochemistry, 2010, 114, 981-993.	3.9	50
98	Toxicology Profile of NÂ-Methyl-d-aspartate Antagonists Delivered by Intrathecal Infusion in the Canine Model. Anesthesiology, 2008, 108, 938-949.	2.5	50
99	Effects of Intrathecal Ketorolac on Human Experimental Pain. Anesthesiology, 2010, 112, 1216-1224.	2.5	47
100	Preclinical Toxicity Screening of Intrathecal Oxytocin in Rats and Dogs. Anesthesiology, 2014, 120, 951-961.	2.5	46
101	Role of Spinal Cyclooxygenase in Human Postoperative and Chronic Pain. Anesthesiology, 2010, 112, 1225-1233.	2.5	46
102	Role of Meningeal Mast Cells in Intrathecal Morphineâ€“evoked Granuloma Formation. Anesthesiology, 2013, 118, 664-678.	2.5	46
103	Intrathecal Ketorolac in Dogs and Rats. Toxicological Sciences, 2004, 80, 322-334.	3.1	45
104	Validation of a Preclinical Spinal Safety Model. Anesthesiology, 2010, 113, 183-199.	2.5	45
105	The Emerging Role of Spinal Dynorphin in Chronic Pain: A Therapeutic Perspective. Annual Review of Pharmacology and Toxicology, 2016, 56, 511-533.	9.4	45
106	Intravenous Lidocaine. Anesthesia and Analgesia, 1997, 85, 794-796.	2.2	44
107	Inhibition of spinal constitutive NOS-2 by 1400W attenuates tissue injury and inflammation-induced hyperalgesia and spinal p38 activation. European Journal of Neuroscience, 2007, 25, 2964-2972.	2.6	44
108	Intrathecal Clonidine in the Neonatal Rat. Anesthesia and Analgesia, 2012, 115, 450-460.	2.2	44

#	Article	IF	Citations
109	Central pharmacology of nociceptive transmission. , 2006, , 371-414.		44
110	Release of Prostaglandin E2 and Nitric Oxide from Spinal Microglia Is Dependent on Activation of p38 Mitogen-Activated Protein Kinase. Anesthesia and Analgesia, 2010, 111, 554-560.	2.2	43
111	Pharmacokinetic Analysis of Ziconotide (SNX-111), an Intrathecal N-Type Calcium Channel Blocking Analgesic, Delivered by Bolus and Infusion in the Dog. Neuromodulation, 2012, 15, 508-519.	0.8	43
112	Safety Assessment of Encapsulated Morphine Delivered Epidurally in a Sustained-Release Multivesicular Liposome Preparation in Dogs. Drug Delivery, 2000, 7, 27-36.	5.7	42
113	Semi-Quantitative Real-Time PCR for Pain Research. , 2004, 99, 225-238.		42
114	Origins of antidromic activity in sensory afferent fibers and neurogenic inflammation. Seminars in Immunopathology, 2018, 40, 237-247.	6.1	42
115	Continuous Intrathecal Administration of Short-lasting micro Opioids Remifentanil and Alfentanil in the Rat. Anesthesiology, 1996, 84, 926-935..	2.5	41
116	An Assessment of the Antinociceptive Efficacy of Intrathecal and Epidural Contulakin-G in Rats and Dogs. Anesthesia and Analgesia, 2007, 104, 1505-1513.	2.2	41
117	Behavioral Models of Pain States Evoked by Physical Injury to the Peripheral Nerve. Neurotherapeutics, 2009, 6, 609-619.	4.4	41
118	Spinal action of dermorphin, an extremely potent opioid peptide from frog skin. Brain Research, 1986, 385, 300-304.	2.2	40
119	Development of a canine nociceptive thermal escape model. Journal of Neuroscience Methods, 2008, 168, 88-97.	2.5	40
120	Systematic analysis of rat 12/15â€lipoxygenase enzymes reveals critical role for spinal eLOX3 hepoxilin synthase activity in inflammatory hyperalgesia. FASEB Journal, 2013, 27, 1939-1949.	0.5	40
121	Resting and Evoked Spinal Substance P Release during Chronic Intrathecal Morphine Infusion: Parallels with Tolerance and Dependence. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 1362-1369.	2.5	39
122	Spinal Neurokinin NK1 Receptor Down-Regulation and Antinociception: Effects of Spinal NK1 Receptor Antisense Oligonucleotides and NK1 Receptor Occupancy. Journal of Neurochemistry, 2002, 70, 688-698.	3.9	38
123	Tissue Injury Models of Persistent Nociception in Rats. , 2004, 99, 25-34.		38
124	Spinal Botulinum Neurotoxin B: Effects on Afferent Transmitter Release and Nociceptive Processing. PLoS ONE, 2011, 6, e19126.	2.5	38
125	Spinal Toll-like receptor signaling and nociceptive processing: Regulatory balance between TIRAP and TRIF cascades mediated by TNF and IFNÎ². Pain, 2013, 154, 733-742.	4.2	37
126	Intrathecal Substance P-Saporin in the Dog. Anesthesiology, 2013, 119, 1163-1177.	2.5	37

#	Article	IF	Citations
127	Preclinical Insights into the Implementation of Intrathecal Midazolam: A Cautionary Tale. Anesthesia and Analgesia, 2004, 98, 1509-1511.	2.2	36
128	Unintended consequences of COVID-19 safety measures on patients with chronic knee pain forced to defer joint replacement surgery. Pain Reports, 2020, 5, e855.	2.7	35
129	Kinetic and Safety Studies on Intrathecally Infused Recombinant-Methionyl Human Brain-Derived Neurotrophic Factor in Dogs. Fundamental and Applied Toxicology, 1997, 38, 89-100.	1.8	34
130	Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics. Anesthesia and Analgesia, 2017, 125, 1714-1732.	2.2	34
131	Studies on spinal opiate receptor pharmacology. III. Analgetic effects of enkephalin dimers as measured by cutaneous-thermal and visceral-chemical evoked responses. Brain Research, 1985, 337, 209-215.	2.2	32
132	Distribution in Cerebrospinal Fluid, Blood, and Lymph of Epidurally Injected Morphine and Inulin in Dogs. Anesthesia and Analgesia, 1986, 65, 583???592.	2.2	32
133	Botulinum toxin in migraine: Role of transport in trigemino-somatic and trigemino-vascular afferents. Neurobiology of Disease, 2015, 79, 111-122.	4.4	32
134	Eicosanoid Production in the Caudate Nucleus and Dorsal Hippocampus after Forebrain Ischemia: A Microdialysis Study. Journal of Cerebral Blood Flow and Metabolism, 1992, 12, 88-95.	4.3	31
135	Thermal hyperalgesia in rat evoked by intrathecal substance P at multiple stimulus intensities reflects an increase in the gain of nociceptive processing. Neuroscience Letters, 1996, 220, 93-96.	2.1	31
136	Fate of the predominant phospholipid component of DepoFoam^{TM}drug delivery matrix after intrathecal administration of sustained-release encapsulated cytarabine in rats. Drug Delivery, 1998, 5, 143-151.	5.7	30
137	The Effects of Intrathecal and Systemic Gabapentin on Spinal Substance P Release. Anesthesia and Analgesia, 2011, 112, 971-976.	2.2	30
138	Treating osteoarthritis pain: mechanisms of action of acetaminophen, nonsteroidal anti-inflammatory drugs, opioids, and nerve growth factor antibodies. Postgraduate Medicine, 2021, 133, 879-894.	2.0	30
139	Spinal Synthesis and Release of Prostanoids After Peripheral Injury and Inflammation. Advances in Experimental Medicine and Biology, 1999, 469, 401-408.	1.6	30
140	Acetaminophen prevents hyperalgesia in central pain cascade. Neuroscience Letters, 2008, 442, 50-53.	2.1	29
141	Role of Toll-like receptor 4 signaling in mast cell-mediated migraineÂpain pathway. Molecular Pain, 2019, 15, 174480691986784.	2.1	29
142	A preclinical post laminectomy rat model mimics the human post laminectomy syndrome. Journal of Neuroscience Methods, 2004, 137, 283-289.	2.5	27
143	Antinociception and Side Effects of Liposome-Encapsulated Alfentanil After Spinal Delivery in Rats. Anesthesia and Analgesia, 1994, 79, 778???786.	2.2	26
144	Halothane Inhibits T Cell Proliferation and Interleukin-2 Receptor Expression in Rats. Immunopharmacology and Immunotoxicology, 1996, 18, 323-336.	2.4	26

#	Article	IF	Citations
145	Temperature Dependency of Basal and Evoked Release of Amino Acids and Calcitonin Gene-Related Peptide from Rat Dorsal Spinal Cord. Journal of Neuroscience, 1997, 17, 4406-4414.	3.6	26
146	Role of spinal p38Î± and Î² MAPK in inflammatory hyperalgesia and spinal COX-2 expression. NeuroReport, 2010, 21, 313-317.	1.2	26
147	Systemic and Spinal Analgesic Activity of a Î´-Opioid-Selective Lanthionine Enkephalin Analog. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 827-832.	2.5	25
148	The need for a journal policy on intrathecal, epidural, and perineural administration of non-approved drugs. Pain, 2010, 149, 417-419.	4.2	25
149	Intrathecal P/Q- and R-type calcium channel blockade of spinal substance P release and c-Fos expression. Neuropharmacology, 2013, 75, 1-8.	4.1	24
150	Effects of Intrathecal SNC80, a Delta Receptor Ligand, on Nociceptive Threshold and Dorsal Horn Substance P Release. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 258-264.	2.5	24
151	Spinal activity of interleukin 6 mediates myelin basic protein-induced allodynia. Brain, Behavior, and Immunity, 2016, 56, 378-389.	4.1	24
152	Mast Cell Degranulation and Fibroblast Activation in the Morphine-induced Spinal Mass. Anesthesiology, 2019, 131, 132-147.	2.5	24
153	An overview of pathways encoding nociception. Clinical and Experimental Rheumatology, 2017, 35 Suppl 107, 40-46.	0.8	24
154	Retrovirus-Mediated Expression of an Artificial Î²-Endorphin Precursor in Primary Fibroblasts. Journal of Neurochemistry, 2002, 64, 475-481.	3.9	23
155	Characteristics of Distribution of Morphine and Metabolites in Cerebrospinal Fluid and Plasma with Chronic Intrathecal Morphine Infusion in Humans. Anesthesia and Analgesia, 2012, 115, 797-804.	2.2	23
156	K/BxN Serum Transfer Arthritis as a Model of Inflammatory Joint Pain. Methods in Molecular Biology, 2012, 851, 249-260.	0.9	23
157	Primary Hydromorphone-Related Intrathecal Catheter Tip Granulomas: Is There a Role for Dose and Concentration?. Neuromodulation, 2016, 19, 760-769.	0.8	23
158	Intravenous Lidocaine. Anesthesia and Analgesia, 1997, 85, 794-796.	2.2	22
159	Spinal amino acid release and repeated withdrawal in spinal morphine tolerant rats. British Journal of Pharmacology, 2003, 138, 689-697.	5.4	21
160	Reciprocal relationship between membrane type 1 matrix metalloproteinase and the algesic peptides of myelin basic protein contributes to chronic neuropathic pain. Brain, Behavior, and Immunity, 2017, 60, 282-292.	4.1	21
161	Quantitation of endogenous substance P by on-line microcolumn liquid chromatography/continuous-flow fast-atom bombardment mass spectrometry. Rapid Communications in Mass Spectrometry, 1989, 3, 43-46.	1.5	20
162	Intrathecal neurosteroids and a neurosteroid antagonist: Effects on inflammation-evoked thermal hyperalgesia and tactile allodynia. Neuroscience Letters, 2013, 548, 27-32.	2.1	20

#	Article	IF	Citations
163	Spinal Nicotinic Receptor Expression in Spontaneously Hypertensive Rats. Hypertension, 1996, 28, 1093-1099.	2.7	19
164	Regulation of spinal nociceptive processing: where we went when we wandered onto the path marked by the gate. Pain, 1999, 82, S149-S152.	4.2	18
165	Effects of Chronic Intrathecal Infusion of a partial Opioid Agonist in Dogs. Toxicological Sciences, 2003, 71, 263-275.	3.1	18
166	Intrathecal Huperzine A increases thermal escape latency and decreases flinching behavior in the formalin test in rats. Neuroscience Letters, 2010, 470, 6-9.	2.1	18
167	Alfentanil: Correlations Between Absence of Effect Upon Subcutaneous Mast Cells and Absence of Granuloma Formation After Intrathecal Infusion in the Dog. Neuromodulation, 2013, 16, 459-466.	0.8	18
168	Micturition in the unanesthetized rat: effects of intrathecal capsaicin, N-vanillylnonanamide, 6-hydroxydopamine and 5,6-dihydroxytryptamine. Brain Research, 1988, 451, 301-308.	2.2	17
169	Synthesis and Biological Activity of a Novel Methylamine-Bridged Enkephalin Analogue (MABE): A New Route to Cyclic Peptides and Peptidomimetics. Journal of Medicinal Chemistry, 1998, 41, 2631-2635.	6.4	17
170	Intrathecal Catheterization and Drug Delivery in Guinea Pigs. Anesthesiology, 2016, 125, 378-394.	2.5	17
171	Neuraxial TNF and IFN-beta co-modulate persistent allodynia in arthritic mice. Brain, Behavior, and Immunity, 2019, 76, 151-158.	4.1	17
172	Role of myelin auto-antigens in pain: a female connection. Neural Regeneration Research, 2016, 11, 890.	3.0	17
173	Characterization of the Effects of L-4-Chlorokynurenine on Nociception in Rodents. Journal of Pain, 2017, 18, 1184-1196.	1.4	16
174	Transient spinal cord ischemia in rat: the time course of spinal FOS protein expression and the effect of intraischemic hypothermia (27 degrees C). Cellular and Molecular Neurobiology, 2000, 20, 351-365.	3.3	15
175	Intrathecal Protease-Activated Receptor Stimulation Produces Thermal Hyperalgesia through Spinal Cyclooxygenase Activity. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 356-363.	2.5	15
176	Target engagement and histopathology of neuraxial resiniferatoxin in dog. Veterinary Anaesthesia and Analgesia, 2018, 45, 212-226.	0.6	15
177	Characterization of Effect of Repeated Bolus or Continuous Intrathecal Infusion of Morphine on Spinal Mass Formation in the Dog. Neuromodulation, 2019, 22, 790-798.	0.8	15
178	A myelin basic protein fragment induces sexually dimorphic transcriptome signatures of neuropathic pain in mice. Journal of Biological Chemistry, 2020, 295, 10807-10821.	3.4	15
179	Pharmacology of Pain and Analgesia. Anaesthesia and Intensive Care, 1980, 8, 248-256.	0.7	14
180	Effects of continuous lumbar intrathecal infusion of leptin in rats on weight regulation. Neuroscience, 2002, 110, 703-710.	2.3	12

#	Article	IF	Citations
181	Effects of opioid and nonopioid analgesics on canine wheal formation and cultured human mast cell degranulation. Toxicology and Applied Pharmacology, 2018, 338, 54-64.	2.8	12
182	Development of New Analgesics: An Answer to Opioid Epidemic. Trends in Pharmacological Sciences, 2018, 39, 1000-1002.	8.7	12
183	Inhibition of spinal 15-LOX-1 attenuates TLR4-dependent, nonsteroidal anti-inflammatory drugâ€“unresponsive hyperalgesia in male rats. Pain, 2018, 159, 2620-2629.	4.2	12
184	A Study and Review of Effects of Botulinum Toxins on Mast Cell Dependent and Independent Pruritus. Toxins, 2018, 10, 134.	3.4	12
185	Intrathecal Drug Delivery: Advances and Applications in the Management of Chronic Pain Patient. Frontiers in Pain Research, 0, 3, .	2.0	12
186	Unilateral Epidural Targeting of Resiniferatoxin Induces Bilateral Neurolysis of Spinal Nociceptive Afferents. Pain Medicine, 2019, 20, 897-906.	1.9	11
187	DRGquant: A new modular AI-based pipeline for 3D analysis of the DRG. Journal of Neuroscience Methods, 2022, 371, 109497.	2.5	11
188	The Pain State Arising From the Laminitic Horse: Insights Into Future Analgesic Therapies. Journal of Equine Veterinary Science, 2010, 30, 79-82.	0.9	10
189	Perineural Local Anesthetic and Adjuvant Action. Regional Anesthesia and Pain Medicine, 2012, 37, 366-368.	2.3	10
190	The neuropathic phenotype of the K/BxN transgenic mouse with spontaneous arthritis: pain, nerve sprouting and joint remodeling. Scientific Reports, 2020, 10, 15596.	3.3	10
191	An overview of pathways encoding nociception. Clinical and Experimental Rheumatology, 2018, 36, 172.	0.8	10
192	Transient tactile allodynia following intrathecal puncture in mouse: Contributions of Toll-like receptor signaling. Neuroscience Letters, 2011, 504, 215-218.	2.1	9
193	The Effects of Intraplantar and Intrathecal Botulinum Toxin Type B on Tactile Allodynia in Mono and Polyneuropathy in the Mouse. Anesthesia and Analgesia, 2015, 121, 229-238.	2.2	9
194	Pharmacology, pharmacokinetics, and metabolism of the DNA-decoy AYX1 for the prevention of acute and chronic post-surgical pain. Molecular Pain, 2017, 13, 174480691770311.	2.1	9
195	Junctional instability in neuroepithelium and network hyperexcitability in a focal cortical dysplasia human model. Brain, 2022, 145, 1962-1977.	7.6	9
196	Antinociception and Side Effects of Lâ€and Dâ€Dipalmitoylphosphatidyl Choline Liposomeâ€Encapsulated Alfentanil after Spinal Delivery in Rats*. Basic and Clinical Pharmacology and Toxicology, 1995, 77, 333-340.	0.0	8
197	Highly potent side chain-main chain cyclized dermorphin-deltorphin analogues: An integrated approach including synthesis, bioassays, NMR spectroscopy and molecular modelling. Journal of Peptide Science, 1995, 1, 157-174.	1.4	8
198	Structural homology of myelin basic protein and muscarinic acetylcholine receptor: Significance in the pathogenesis of complex regional pain syndrome. Molecular Pain, 2018, 14, 174480691881500.	2.1	8

#	Article	IF	Citations
199	SPINAL NICOTINIC RECEPTOR ACTIVITY IN A GENETIC MODEL OF HYPERTENSION. Clinical and Experimental Hypertension, 2001, 23, 555-568.	1.3	7
200	Spinal antinociceptive action of loperamide is mediated by opioid receptors in the formalin test in rats. Neuroscience Letters, 2008, 448, 260-262.	2.1	7
201	Development and validation of an automated system for detection and assessment of scratching in the rodent. Journal of Neuroscience Methods, 2012, 211, 1-10.	2.5	7
202	Bacteria get on your nerves. Nature, 2013, 501, 43-44.	27.8	7
203	Analgesic properties of intrathecal glucocorticoids in three well established preclinical pain models. Scandinavian Journal of Pain, 2016, 10, 90-102.	1.3	7
204	Effects of intraplantar botulinum toxinâ€B on carrageenanâ€induced changes in nociception and spinal phosphorylation of GluA1 and Akt. European Journal of Neuroscience, 2016, 44, 1714-1722.	2.6	6
205	Systematic Review of Systemic and Neuraxial Effects of Acetaminophen in Preclinical Models of Nociceptive Processing. Journal of Pain Research, 2021, Volume 14, 3521-3552.	2.0	6
206	Effect of Needle Combination on the Analgesic Efficacy of the Tendinomuscular Meridians (TMM) System. Medical Acupuncture, 2007, 19, 191-200.	0.6	5
207	Editorâ€™s Highlight: Formulation and Toxicology Evaluation of the Intrathecal AYX1 DNA-Decoy in Sprague Dawley Rats. Toxicological Sciences, 2017, 159, 76-85.	3.1	5
208	Effect of intrathecal glucocorticoids on the central glucocorticoid receptor in a rat nerve ligation model. Scandinavian Journal of Pain, 2017, 16, 1-9.	1.3	5
209	Characterization of Analgesic Actions of the Chronic Intrathecal Infusion of H-Dmt-D-Arg-Phe-Lys-NH2 in Rat. Neuromodulation, 2019, 22, 781-789.	0.8	5
210	The Spinal Pharmacology of Urinary Function: Studies on Urinary Continence in the Unanaesthetized Rat. Novartis Foundation Symposium, 1990, 151, 91-118.	1.1	5
211	Future advances in pain pharmacology: what does the present say about the future?. Proceedings of the Western Pharmacology Society, 2002, 45, 211-8.	0.1	5
212	Effects of spinal naloxone and naltrindole on the antinociceptive action of intrathecally administered dexmedetomidine. Journal of Anesthesia, 1996, 10, 194-198.	1.7	4
213	Consent Contraindicated?. Science, 2010, 328, 45-45.	12.6	4
214	Sexual Dimorphism in the Expression of Pain Phenotype in Preclinical Models of Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2021, 47, 245-264.	1.9	4
215	Analgesics, Pain and Tolerance: The St John's Discussion. Pain Research and Management, 2000, 5, 19-22.	1.8	3
216	Ziconotide. CNS Drugs, 2006, 20, 340-341.	5.9	3

#	Article	IF	Citations
217	Ethical Concerns Regarding Human Study. CNS Neuroscience and Therapeutics, 2016, 22, 866-866.	3.9	3
218	Complexity of systems and actions underlying neurogenic inflammation. Seminars in Immunopathology, 2018, 40, 225-228.	6.1	3
219	Spinal ExparelÂ®â€"an extended duration of preclinical study needed. British Journal of Anaesthesia, 2019, 122, 298-300.	3.4	3
220	Characterization of the antinociceptive effects of intrathecal DALDA peptides following bolus intrathecal delivery. Scandinavian Journal of Pain, 2019, 19, 193-206.	1.3	3
221	Pharmacodynamics of intrathecal and epidural fadolmidine, an Î±2-adrenoceptor agonist, after bolus and infusion in dogsâ€"comparison with clonidine. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 1459-1473.	3.0	3
222	Sex-Specific B Cell and Anti-Myelin Autoantibody Response After Peripheral Nerve Injury. Frontiers in Cellular Neuroscience, 2022, 16, 835800.	3.7	3
223	A Survey of Systems Involved in Nociceptive Processing. , 2013, , 3-21.		2
224	Frontiers in Pain Research: A Scope of Its Focus and Content. Frontiers in Pain Research, 2020, 1, 601528.	2.0	2
225	Evaluation of neurotoxicity and long-term function and behavior following intrathecal 1 % 2-chloroprocaine in juvenile rats. NeuroToxicology, 2022, 88, 155-167.	3.0	2
226	Role of the intrinsic modulatory systems in somesthesis. Behavioral and Brain Sciences, 1980, 3, 315-315.	0.7	1
227	Letter to Editor re: â€œUnique Intradural Inflammatory Mass Containing Precipitated Morphineâ€•by Kim etÂal.. Pain Practice, 2019, 19, 456-456.	1.9	1
228	Topical Application of ASN008, a Permanently-charged Sodium Channel Blocker, Shows Robust Efficacy, a Rapid Onset and Long Duration of Action in a Mouse Model of Pruritus. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, jpet.120.265074.	2.5	1
229	Leakage of fluid after epidural injection. Pain, 1991, 44, 325.	4.2	0
230	Pharmacology of Facilitated Nociceptive Processing. Journal of Musculoskeletal Pain, 1996, 4, 201-221.	0.3	0
231	Spinal Tolerance and Dependence: Some Observations on the Role of SpinalN-Methyl-D-Aspartate Receptors and Phosphorylation in the Loss of Opioid Analgesic Responses. Pain Research and Management, 2000, 5, 33-39.	1.8	0
232	Prostanoids in Pain. , 0, , 473-480.		0
233	Pain mechanisms in animal models of rheumatoid arthritis. Scandinavian Journal of Pain, 2010, 1, 168-169.	1.3	0
234	Care to wrestle with a Brazilian armed spider?. Pain, 2011, 152, 2193-2195.	4.2	0

#	Article	IF	Citations
235	TRPV1 expression regulationâ€¦ A further step in defining its biology. Neuroscience Letters, 2014, 578, 209-210.	2.1	0
236	Evolution of the Spinal Delivery of Opiate Analgesics. , 2018, , 803-817.		0
237	Role of neuraxial drug delivery in cancer pain therapy. Future Drug Discovery, 2020, 2, FDD49.	2.1	0
238	FarmacologÃa central de la transmisiÃ³n nociceptiva. , 2007, , 379-423.		0
239	Profiling of lipid mediators released spinally in response to peripheral painful inflammation. FASEB Journal, 2008, 22, 1040.2.	0.5	0
240	Repeated Low-Dose Acrolein Triggers Irreversible Lamina Propria Edema in Urinary Bladder, Transient Voiding Behavior and Widening of Eyes to Mechanical Stimuli. Cells, 2021, 10, 3477.	4.1	0